17 / 54
ESTUDIO OAK
SUPERVIVENCIA POR EXPRESIÓN DE PD-L1
0,2
2
In favor of
docetaxel
Hazard Ratio
a
In favor of
atezolizumab
Subgroup
Median OS, mo
Atezolizumab Docetaxel
n = 425
n = 425
0.2 1 2
TC1/2/3 or IC1/2/3
a
TC0 and IC0
ITT
a
TC3 or IC3
TC2/3 or IC2/3
13.8
9.6
12.6
8.9
15.7
10.3
16.3
10.8
20.5
8.9
0.41
0.67
0.74
0.75
0.73
0%
20%
40%
60%
80%
100%
16%
31%
55%
100%
45%
On-study Prevalence
Barlesi et al, ESMO 2016